Complete Filing Data
Pelthos Therapeutics Inc. reported Stockholders Equity of $38.88 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Pelthos Therapeutics Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue * | $16.8M | $0.00 | ||
| Net Income Loss | -$43.3M | -$8.0M | -$7.4M | -$2.5M |
| Research And Development Expense | $1.2M | $1.2M | $2.6M | $391.7K |
| Operating Income Loss | -$32.4M | -$7.6M | -$6.9M | -$2.3M |
| Nonoperating Income Expense | -$18.3M | -$384.0K | -$518.5K | -$140.4K |
| Operating Expenses | $7.6M | $6.9M | $2.3M | |
| Interest Expense On Promissory Note Related Party | $786.4K | $518.5K | $140.4K | |
| General And Administrative Expense | $4.1M | $2.7M | $1.1M | |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | -$7.4M | -$2.5M | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$50.7M | -$8.0M | ||
| Selling General And Administrative Expense | $42.5M | $6.4M | ||
| Interest Expense | ||||
| Income Tax Expense Benefit | -$7.4M | $0.00 | ||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | ||||
| Cost Of Goods And Services Sold | $4.0M | $0.00 | ||
| Amortization Of Intangible Assets | $1.6M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue * | $294.0K | ||||||||
| Net Income Loss | -$16.2M | -$3.4M | -$2.0M | -$1.7M | -$1.8M | -$2.6M | -$1.4M | -$953.3K | -$966.6K |
| Research And Development Expense | $145.0K | $514.8K | $194.3K | $415.0K | $13.0K | $466.6K | $49.1K | $50.0K | $186.1K |
| Operating Income Loss | -$15.4M | -$3.2M | -$1.8M | -$2.0M | -$1.8M | -$1.9M | -$1.3M | -$777.2K | -$914.6K |
| Nonoperating Income Expense | -$1.3M | -$218.5K | -$133.6K | $354.0K | -$7.5K | -$628.3K | -$130.0K | -$176.2K | -$52.0K |
| Operating Expenses | $22.8M | $3.2M | $1.8M | $2.0M | $1.8M | $1.9M | $1.3M | $777.2K | $914.6K |
| Interest Expense On Promissory Note Related Party | $218.5K | $133.6K | $39.0K | $11.1K | $628.3K | $130.0K | $176.2K | $52.0K | |
| General And Administrative Expense | $1.1M | $1.1M | $1.2M | $1.2M | $787.6K | $661.6K | $537.9K | $477.6K | |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | -$1.7M | -$1.8M | -$2.6M | -$1.4M | -$953.3K | -$966.6K | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$16.7M | -$3.4M | -$2.0M | -$1.7M | -$1.8M | -$2.6M | |||
| Selling General And Administrative Expense | $19.6M | $1.6M | |||||||
| Interest Expense | $1.3M | $39.0K | |||||||
| Income Tax Expense Benefit | -$465.0K | ||||||||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$16.2M | -$1.7M | |||||||
| Cost Of Goods And Services Sold | $2.3M | ||||||||
| Amortization Of Intangible Assets | $679.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stockholders Equity | $38.9M | -$2.7M | -$6.4M | -$3.7M | -$3.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $55.1K | ||||
| Amortization Of Debt Discount Premium | $259.0K | $692.0K | $188.1K | $140.4K | |
| Retained Earnings Accumulated Deficit | -$64.8M | -$21.5M | -$13.5M | -$6.1M | |
| Liabilities Current | $26.0M | $4.1M | $6.5M | $3.8M | |
| Liabilities And Stockholders Equity | $130.4M | $1.4M | $96.4K | $55.1K | |
| Liabilities | $91.5M | $4.1M | $6.5M | $3.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $17.5M | $417.0K | $41.3K | $55.1K | |
| Assets Current | $53.4M | $1.4M | $96.4K | $55.1K | |
| Assets | $130.4M | $1.4M | $96.4K | $55.1K | |
| Common Stock Value | $0.00 | $0.00 | $391.00 | $111.00 | |
| Cash | $18.0M | $513.0K | |||
| Loans Payable | $750.1K | $104.8K | |||
| Accounts Payable And Accrued Liabilities Current | $4.6M | $3.0M | |||
| Other Loans Payable | $202.3K | ||||
| Accrued Liabilities Current | $15.4M | $0.00 | $645.9K | $221.9K | |
| Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction | $1.1M | $0.00 | $428.4K | ||
| Cash And Due From Banks | |||||
| Stock Issued During Period Value Transfer Of Liabilities To Chromocell Corp.For Preferred C Shares | 2.2M | ||||
| Stock Issued During Period Value Recission Of Common Stock | -$91.5K | ||||
| Deferred Offering Costs | |||||
| Transfer Of Investments | $2.2M | ||||
| Conversion Of Notes To Common Stock | |||||
| PIPE Proceeds Allocated To Debt Payable | $20.3M | $0.00 | |||
| Accounts Payable Current | $3.0M | $1.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $58.3M | -$6.5M | -$4.2M | -$1.4M | -$184.0K | $1.1M | -$5.9M | -$4.9M | -$4.4M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $14.3M | $59.2K | $131.3K | $513.0K | $1.3M | $2.4M | $3.8M | $96.0K | $22.8K | $81.9K | $48.6K | |
| Amortization Of Debt Discount Premium | $94.2K | $605.6K | $31.7K | $150.0K | ||||||||
| Retained Earnings Accumulated Deficit | -$43.1M | -$26.9M | -$23.4M | -$19.5M | -$17.9M | -$16.1M | ||||||
| Liabilities Current | $24.8M | $7.3M | $5.1M | $3.6M | $2.8M | $2.9M | ||||||
| Liabilities And Stockholders Equity | $126.4M | $822.9K | $911.2K | $2.1M | $2.6M | $4.0M | ||||||
| Liabilities | $68.2M | $7.3M | $5.1M | $3.6M | $2.8M | $2.9M | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$382.1K | $3.7M | -$6.5K | |||||||||
| Assets Current | $49.8M | $822.9K | $911.2K | $2.1M | $2.6M | $4.0M | ||||||
| Assets | $126.4M | $822.9K | $911.2K | $2.1M | $2.6M | $4.0M | ||||||
| Common Stock Value | $67.00 | $621.00 | $583.00 | $584.00 | $578.00 | |||||||
| Cash | ||||||||||||
| Loans Payable | $131.9K | $131.9K | $132.0K | $131.9K | $131.9K | |||||||
| Accounts Payable And Accrued Liabilities Current | $5.0M | $2.6M | $1.9M | $1.3M | $835.4K | $2.4M | ||||||
| Other Loans Payable | $2.2M | $2.4M | $2.1M | $2.2M | $1.5M | |||||||
| Accrued Liabilities Current | $11.9M | $23.6K | $308.00 | $363.4K | $493.9K | |||||||
| Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction | $447.8K | |||||||||||
| Cash And Due From Banks | $40.4K | $40.4K | $40.4K | $40.4K | $40.4K | $40.4K | ||||||
| Stock Issued During Period Value Transfer Of Liabilities To Chromocell Corp.For Preferred C Shares | 2.2M | |||||||||||
| Stock Issued During Period Value Recission Of Common Stock | -$92.0K | |||||||||||
| Deferred Offering Costs | $710.9K | $723.1K | $750.0K | $750.0K | ||||||||
| Transfer Of Investments | $2.2M | |||||||||||
| Conversion Of Notes To Common Stock | $1.4M | |||||||||||
| PIPE Proceeds Allocated To Debt Payable | ||||||||||||
| Accounts Payable Current | $5.7M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Share Based Compensation | $5.5M | $1.8M | $1.7M | $110.1K |
| Net Cash Provided By Used In Operating Activities | -$22.6M | -$5.8M | -$981.0K | -$1.6M |
| Net Cash Provided By Used In Financing Activities | $45.3M | $6.2M | $1.0M | $1.6M |
| Increase Decrease In Accrued Liabilities | $6.2M | -$283.0K | $424.1K | $221.9K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $1.2M | $1.6M | $413.6K | |
| Proceeds From Debt Net Of Issuance Costs | $693.0K | $536.0K | $201.0K | |
| Proceeds From Issuance Of Common Stock | $0.00 | $6.0M | $255.4K | |
| Increase Decrease In Prepaid Expense | $880.0K | $861.0K | ||
| Proceeds From Repayments Of Debt | -$214.8K | $300.0K | ||
| Proceeds From Related Party Debt | $565.9K | $100.0K | ||
| Payments For Repurchase Of Equity | $91.5K | |||
| Proceeds From PIPE Net | $27.4M | $0.00 | ||
| Increase Decrease In Accounts Payable | $1.4M | $1.2M | ||
| Stock Issued During Period Value Share Based Compensation Forfeited | $13.00 | |||
| Net Cash Provided By Used In Investing Activities | -$5.2M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|
| Share Based Compensation | $485.8K | $292.6K | $272.2K |
| Net Cash Provided By Used In Operating Activities | -$632.1K | -$2.0M | -$173.4K |
| Net Cash Provided By Used In Financing Activities | $250.0K | $5.7M | $166.9K |
| Increase Decrease In Accrued Liabilities | -$152.0K | $122.0K | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $706.5K | $91.0K | $367.3K |
| Proceeds From Debt Net Of Issuance Costs | $250.0K | ||
| Proceeds From Issuance Of Common Stock | $6.0M | ||
| Increase Decrease In Prepaid Expense | -$49.0K | $220.9K | |
| Proceeds From Repayments Of Debt | -$214.8K | ||
| Proceeds From Related Party Debt | $166.9K | ||
| Payments For Repurchase Of Equity | $91.5K | ||
| Proceeds From PIPE Net | |||
| Increase Decrease In Accounts Payable | |||
| Stock Issued During Period Value Share Based Compensation Forfeited | |||
| Net Cash Provided By Used In Investing Activities |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 1.9M | 557.4K | 1.3M | 435.3K |
| Earnings Per Share Basic | $-23.04 | $-14.27 | $-5.78 | $5.65 |
| Common Stock Shares Outstanding | 3.2M | 610.4K | 3.9M | 1.1M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Issued | 3.2M | 610.4K | 3.9M | 1.1M |
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 100.0M |
| Weighted Average Number Of Diluted Shares Outstanding | 1.9M | 557.4K | 1.3M | |
| Earnings Per Share Diluted | $-23.04 | $-14.27 | $-5.78 | |
| Debt Discount From Shares Issued On Extension Of Bridge Loan | 428.4K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 3.1M | 640.5K | 6.1M | 579.2K | 577.4K | 4.7M | 984.5K | 1.0M | 1.1M | |
| Earnings Per Share Basic | $-5.30 | $-5.38 | $-0.32 | $-2.93 | $-3.07 | $-0.55 | $-1.44 | $-0.95 | $-0.87 | |
| Common Stock Shares Outstanding | 3.1M | 673.3K | 6.2M | 5.8M | 5.8M | 5.8M | 118.7K | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $377.10 | |||
| Common Stock Shares Issued | 3.1M | 673.3K | 6.2M | 5.8M | 5.8M | 5.8M | ||||
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | ||||
| Weighted Average Number Of Diluted Shares Outstanding | 3.1M | 640.5K | 6.1M | 579.2K | 577.4K | 4.7M | ||||
| Earnings Per Share Diluted | $-5.30 | $-5.38 | $-0.32 | $-2.93 | $-3.07 | $-0.55 | ||||
| Debt Discount From Shares Issued On Extension Of Bridge Loan | 447.8K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $4.0M | $1.5M | $1.7M | $110.1K |
| Stock Issued During Period Value Issued For Services | $53.0K | $239.0K | $255.4K | |
| Professional Fees | $2.3M | $1.5M | $827.6K | |
| Additional Paid In Capital | $103.7M | $18.8M | $7.1M | $2.4M |
| Stock Issued During Period Value Restricted Stock Award Gross | $1.5M | $105.0K | ||
| Other Income | $39.4K | |||
| Stock Issued During Period Value New Issues | $38.7M | $428.4K | ||
| Prepaid Expense Current | ||||
| Stock Issued During Period Value Conversion Of Units | $1.4M | |||
| Due To Chromocell Corporation | $5.4K | $5.4K | ||
| Due From Chromocell Corporation | -$45.8K | |||
| Bridge Loan | $316.3K | $435.6K | ||
| Interest Paid Net | $19.0K | $0.00 | ||
| Stock Issued During Period Shares Stock Options Exercised | 20.5K | 0.00 | ||
| Conversion Of Notes | $1.4M | |||
| Stock Repurchased During Period Value | $74.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.0M | $342.0K | $404.0K | $395.0K | $366.0K | $293.0K | $342.4K | $327.3K | $272.2K | |
| Stock Issued During Period Value Issued For Services | $20.0K | $30.0K | $81.0K | $78.0K | $6.0M | |||||
| Professional Fees | $1.6M | $549.6K | $472.6K | $541.3K | $679.8K | $581.0K | $189.3K | $250.8K | ||
| Additional Paid In Capital | $101.4M | $20.4M | $19.2M | $18.1M | $17.7M | $17.2M | ||||
| Stock Issued During Period Value Restricted Stock Award Gross | $811.0K | $52.0K | $52.0K | $42.0K | $14.0K | |||||
| Other Income | $5.0K | $393.0K | $3.5K | |||||||
| Stock Issued During Period Value New Issues | $6.0M | $75.6K | $126.0K | |||||||
| Prepaid Expense Current | $3.4M | $12.3K | $16.3K | $856.0K | $94.6K | $158.1K | $220.9K | |||
| Stock Issued During Period Value Conversion Of Units | $737.0K | $1.4M | ||||||||
| Due To Chromocell Corporation | ||||||||||
| Due From Chromocell Corporation | -$45.8K | |||||||||
| Bridge Loan | ||||||||||
| Interest Paid Net | $11.3K | |||||||||
| Stock Issued During Period Shares Stock Options Exercised | ||||||||||
| Conversion Of Notes | $1.4M | |||||||||
| Stock Repurchased During Period Value | $74.0K |
Most recent annual filing with the SEC: March 19, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.